verubecestat

^[1]^[2]^[3]

Contraindications

mild-moderate Alzheimer's disease
- does not reduce cognitive or functional decline^[2]
- associated with treatment-related adverse events^[2]

↑ Thaisrivongs DA, Morris WJ, Tan L, Song ZJ et al A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931). Org Lett. 2018 Mar 16;20(6):1568-1571. Epub 2018 Feb 26. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29481097
↑ ^2.0 ^2.1 ^2.2 Egan MF, Kost J, Tariot PN et al Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med 2018; 378:1691-1703. May 3, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29719179 https://www.nejm.org/doi/full/10.1056/NEJMoa1706441
↑ Egan MF, Kost J, Voss T et al Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. N Engl J Med 2019; 380:1408-1420. April 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30970186 https://www.nejm.org/doi/full/10.1056/NEJMoa1812840